G1 Therapeutics, Inc. (NASDAQ:GTHX) Q4 2022 Earnings Call Transcript

Andrew Perry: Yes, so what’s driving it is the rate of increase that we have seen and our success, mainly in these community clinics, and the rate of continued adoption in new accounts and our estimate of how that will extend through the year, based on what we’ve learned so far about the Cosela pattern of adoption. Again, I would say that the single biggest thing that will drive our success in this market is when we move quickly from trial to adoption, the first patient to multiple patients and then multiple accounts within an organization with multiple patients, we’ve seen great success over the last few months with that strategy. We’re doubling down on that strategy going into this year and our forecast is really based on that dynamic. I think it’s important to remember, this is a several hundred million dollar market, $700 million market. We are scratching the surface of the potential here. There is plenty of room for us to grow and achieve these targets.

Priyanka Grover: Understood, thank you so much.

Operator: Thank you. I’m showing no further questions, so with that, I’ll hand the call back over to CEO, Jack Bailey for any closing remarks.

Jack Bailey: Great, thank you Operator. As always, we look forward to keeping everybody updated on our progress, but for now, that concludes this call. Thank you for joining us today. We’ll look forward to being in touch.

Operator: Ladies and gentlemen, this does conclude today’s program. You may now disconnect.